REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	199.55B
Revenue (ttm)	149.34B
Net Income (ttm)	-14.25B
Shares Out	18.34M
EPS (ttm)	-774.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,482
Average Volume	23,809
Open	10,460
Previous Close	10,730
Day's Range	10,300 - 10,670
52-Week Range	9,830 - 15,170
Beta	0.58
RSI	50.80
Earnings Date	Nov 14, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 312
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2024, REYON Pharmaceutical's revenue was 148.30 billion, a decrease of -1.83% compared to the previous year's 151.07 billion. Earnings were 4.15 billion, an increase of 15.85%.